+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2019: Deal Trends, Players and Financials

  • ID: 2336340
  • Report
  • Region: Global
  • 300 Pages
  • CurrentPartnering
1 of 3
Antibody partnering activity rises by 13.6%, read about this and other trends in the antibody industry.

FEATURED COMPANIES

  • 3SBio
  • Alligator Bioscience
  • AstraZeneca
  • Biomunex Pharmaceuticals
  • Cipla
  • Distributed Bio
  • MORE
The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in cancer monoclonal antibody partnering deals
  • Most active companies in cancer monoclonal antibody partnering
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value
This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits
  • In-depth understanding of cancer monoclonal antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify most active companies in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Spot the emerging companies in the cancer monoclonal antibody area
Report Scope
Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:
Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2014
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 360 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2014

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio
  • Alligator Bioscience
  • AstraZeneca
  • Biomunex Pharmaceuticals
  • Cipla
  • Distributed Bio
  • MORE
1. Introduction

2. Trends in Cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active Cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for Cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates

3. Leading Cancer monoclonal antibody deals
3.1. Introduction
3.2. Top Cancer monoclonal antibody deals by value

4. Most active Cancer monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active Cancer monoclonal antibody dealmakers
4.3. Most active Cancer monoclonal antibody partnering company profiles

5. Cancer monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory

6. Cancer monoclonal antibody dealmaking by technology type

7. Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Cancer monoclonal antibody deals by company A-Z
Appendix 2 – Cancer monoclonal antibody deals by stage of development
Appendix 3 – Cancer monoclonal antibody deals by deal type
Appendix 4 – Cancer monoclonal antibody deals by therapy area
Appendix 5 – Deal type definitions

Table of Figures
Figure 1: Therapeutic antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2014
Figure 3: Active Cancer monoclonal antibody dealmaking activity since 2014
Figure 4: Cancer monoclonal antibody partnering by deal type since 2014
Figure 5: Cancer monoclonal antibody partnering by disease type since 2014
Figure 6: Cancer monoclonal antibody deals with a headline value
Figure 7: Cancer monoclonal antibody deals with an upfront value
Figure 8: Cancer monoclonal antibody deals with a milestone value
Figure 9: Cancer monoclonal antibody deals with a royalty rate value
Figure 10: Top Cancer monoclonal antibody deals by value since 2014
Figure 11: Most active Cancer monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3SBio
  • 4D Pharma
  • Abbvie
  • AbClon
  • Abpro
  • Abzena
  • Accord Healthcare
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Adaptive Biotechnologies
  • Adlai Nortye
  • Aduro BioTech
  • Advantagene
  • Advaxis
  • Aeglea BioTherapeutics
  • AffaMed Therapeutics
  • Affimed Therapeutics
  • Affinita Biotech
  • AGC Biologics
  • Agenus Bio
  • Alligator Bioscience
  • Alvogen
  • Ambrx
  • Amgen
  • Amneal Pharmaceuticals
  • AnaptysBio
  • Anthera Pharmaceuticals
  • Antigen Express
  • Apceth
  • Apeiron Biologics
  • Aperion Biologics
  • Apexigen
  • arGEN-X
  • argenx
  • Array Biopharma
  • Ascenion
  • Ascentage Pharma
  • Aslan Pharma
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atara Biotherapeutics
  • Athenex
  • Atlab Pharma
  • AVEO Oncology
  • Aytu BioScience
  • Basilea Pharmaceutica
  • Bavarian Nordic
  • Baxalta
  • BeiGene
  • BerGenBio
  • Biametrics
  • Bio-Thera Solutions
  • BioAtla
  • Bioceros
  • BiocerOX Products
  • Biodesix
  • Bio Farma
  • BioInvent
  • BiolineRX
  • BioMarker Strategies
  • Biomunex Pharmaceuticals
  • Biothera
  • BioXcel
  • BliNK Biomedical
  • BliNK Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • C-Bridge Capital
  • Calithera Biosciences
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK
  • CBT Pharmaceuticals
  • CDI Laboratories
  • Celgene
  • Celldex Therapeutics
  • Cell Signaling Technology
  • Celltrion
  • Centre for Drug Research and Development (CDRD)
  • Checkmate Pharmaceuticals
  • Chiome Bioscience
  • Cilag AG
  • Cipla
  • Clal Biotech
  • Clinica Universidad Navarra
  • Clovis Oncology
  • Cold Genesys
  • Columbia University
  • Compugen
  • Conkwest
  • Corvus Pharmaceuticals
  • Covalab
  • Crescendo Biologics
  • Crown Bioscience
  • CStone Pharmaceuticals
  • Cullinan Oncology
  • CureTech
  • Curie-Cancer
  • CytomX Therapeutics
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dako
  • Debiopharm
  • Distributed Bio
  • DNAtrix
  • Dynavax Technologies
  • eFFECTOR Therapeutics
  • Eisai
  • Eleven Biotherapeutics
  • Eli Lilly
  • ElsaLys Biotech
  • EMD Millipore
  • EMD Serono
  • Enumeral Biomedical
  • Enzo Biochem
  • EpiThany
  • Essex Bio-Technology
  • Eureka Therapeutic
  • Eurofarma
  • EUSA Pharma
  • Eutilex
  • Faron Pharmaceuticals
  • Fate Therapeutics
  • Five Prime Therapeutics
  • FLX Bio
Sample list of companies, more included in the report
Note: Product cover images may vary from those shown
Adroll
adroll